Methods and compositions for treating cancer

EP4429653A4Pending Publication Date: 2025-10-29REVERSPAH LLC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
EP2022893834
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-10
Filing Date
2022-11-10
Publication Date
2025-10-29

AI Technical Summary

Technical Problem

Current cancer treatments face challenges in effectively targeting angiogenesis and inflammation, with existing therapies often having limited efficacy and side effects, particularly in regulating copper levels and managing inflammation in cancer patients.

Method used

The use of a copper chelator, tetrathiomolybdate (TTM), in combination with diethylcarbamazine (DEC) and astaxanthin (ATX), administered in an enteric-coated, extended-release formulation to control copper levels and reduce inflammation, thereby inhibiting angiogenesis and inflammation pathways.

Benefits of technology

This approach provides a more effective and controlled release of TTM, reducing side effects and enhancing bioavailability, leading to improved treatment outcomes for cancer and pulmonary arterial hypertension by inhibiting angiogenesis and inflammation, and improving patient compliance with once-a-day dosing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000021_0001
    Figure IMGF000021_0001
  • Figure IMGF000021_0002
    Figure IMGF000021_0002
  • Figure IMGF000024_0001
    Figure IMGF000024_0001
Patent Text Reader

Abstract

Pharmaceutical compositions containing tetrathiomolybdate (TTM) are disclosed. Pharmaceutical compositions and formulations that contain TTM along with other co-drugs, such as diethylcarbamazine (DEC) and astaxanthin (ATX), are also disclosed. Formulations include a delayed release oral form that releases the TTM in the gastrointestinal tract after the oral form passes the stomach, and an enteric oral form that is not a delayed release form are disclosed. Methods of treating cancer, treating cancer patients as an adjuvant therapy, and treating pulmonary arterial hypertension by administering the pharmaceutical compositions are further disclosed.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases

    US20070207191A1

  • Targeted gastrointestinal tract delivery of probiotic organisms and / or therapeutic agents

    US20160022592A1

  • Method of treating severe forms of pulmonary hypertension

    US20200405748A1